Clinical features of hemophagocytic syndrome in patients with dermatomyositis

Journal of Rheumatology

Volumn 35, Issue 9, 2008, Pages 1838-1841

  Yajima, Nobuyuki ^a   Wakabayashi, Kuninobu ^a   Odai, Tsuyoshi ^a   Isozaki, Takeo ^a   Matsunawa, Mizuho ^a   Miwa, Yusuke ^a   Negishi, Masao ^a   Ide, Hirotsugu ^a   Kasama, Tsuyoshi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CX3CL1; Cytokine; Dermatomyositis; Hemophagocytic syndrome

Indexed keywords

COLONY STIMULATING FACTOR 1; CREATINE KINASE; FERRITIN; FRACTALKINE; INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; FEMALE; FERRITIN BLOOD LEVEL; HEMOPHAGOCYTIC SYNDROME; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; CHEMOKINE CX3CL1; CREATINE KINASE; DERMATOMYOSITIS; FERRITINS; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2;

EID: 54049092509     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124-31.
2. Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003;15:587-90.
3. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 2004;3:69-75.
4. Yasuda S, Tsutsumi A, Nakabayashi T, et al. Haemophagocytic syndrome in a patient with dermatomyositis. Br J Rheumatol 1998;37:1357-8.
5. Kobayashi I, Yamada M, Kawamura N, Kobayashi R, Okano M, Kobayashi K. Platelet-specific hemophagocytosis in a patient with juvenile dermatomyositis. Acta Paediatr 2000;89:617-9.
6. Madaule S, Porte L, Couret B, Arlet-Suau E. Fatal haemophagocytic syndrome in the course of dermatomyositis with anti-Mi2 antibodies. Rheumatology Oxford 2000;39:1157-8.
7. Sterba G, Rodriguez C, Sifontes S, Vigilanza P. Macrophage activation syndrome due to methotrexate in a 12-year-old boy with dermatomyositis. J Rheumatol 2004;31:1014-5.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;13;292:344-7.
9. Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 1999;11:475-82.
10. Gonzalez-Amaro R, Alcocer-Varela J, Alarcon-Segovia D. Natural killer cell activity in dermatomyositis-polymyositis. J Rheumatol 1987;14:307-10.
11. Wong KF, Hui PK, Chan JLC. The acute lupus hemophagocytic syndrome. Ann Intern Med 1991;114:387-90.
12. Kumakura S, Ishikura H, Umegae N. Autoimmune-associated hemophagocytic syndrome. Am J Med 1997;102:113-5.
13. Suzuki F, Nanki T, Imai T, et al. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J Immunol 2005;175:6987-96.
14. Ruth JH, Volin MV, Haines GK 3rd, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-81.
15. Matsunawa M, Isozaki T, Odai T, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 2006;54:3408-16.